Peng Changlan, Li Chunxiao, Zhou Yingying, Wang Qiuyue, Xie Ping, Li Tianhao, Hao Pingsheng
Department of Dermatology, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Clin Cosmet Investig Dermatol. 2022 Mar 21;15:503-506. doi: 10.2147/CCID.S354025. eCollection 2022.
Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored.
We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.
This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis.
JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.
尽管近年来结节性痒疹的治疗取得了进展，但传统治疗仍面临疗效不佳的困境。Janus激酶（JAK）抑制剂在结节性痒疹治疗中的临床应用鲜有探索。
我们报告1例结节性痒疹患者成功接受JAK抑制剂托法替布治疗且无不良反应。
本成功治疗的病例报告显示，JAK抑制剂托法替布治疗结节性痒疹具有良好的临床疗效。细胞因子可能是结节性痒疹的重要病因。
JAK抑制剂托法替布可能是结节性痒疹治疗的新选择，尤其是对传统治疗无效的患者。
